San Jose, CA, United States
San Jose, CA, United States

Time filter

Source Type

Receive press releases from iHealthcareAnalyst, Inc.: By Email Cervical Dysplasia Diagnostics Market by Diagnosis Type, Diagnostic Device, End Users and Forecast to 2021, Upcoming Findings by iHealthcareAnalyst, Inc. Cervical Dysplasia Diagnostics Market by Diagnosis Type (Diagnosis Test - Biopsy, HPV Test, Pap Smear Test), Diagnostic Device (Colposcopy), End Users (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, Private Gynecologists’ Offices, Research & Academic Institutes) and Forecast to 2021 Maryland Heights, MO, April 19, 2017 --( Browse Cervical Dysplasia Diagnostics Market by Diagnosis Type (Diagnosis Test - Biopsy, HPV Test, Pap Smear Test), Diagnostic Device (Colposcopy), End Users (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, Private Gynecologists’ Offices, Research & Academic Institutes) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/cervical-dysplasia-diagnostics-market/ The global cervical dysplasia diagnostics market segmentation is based on diagnosis type (diagnosis test - biopsy, HPV test, Pap smear test), diagnostic device (colposcopy), end users (ambulatory surgical centers, diagnostic centers, hospitals, private gynecologists’ offices, research & academic institutes). The global cervical dysplasia diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global cervical dysplasia diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global cervical dysplasia diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global cervical dysplasia diagnostics market and profiled in this report include Abbott Laboratories, Becton, Dickinson and company, F. Hoffmann La-Roche Ltd., Hologic, Inc., Micromedic Technologies Ltd., OncoHealth Corporation, QIAGEN N.V., and Quest Diagnostics, Inc. 1. Diagnosis Type 1.1. Diagnosis Test 1.1.1. Biopsy 1.1.2. HPV Test 1.1.3. Pap Smear Test 1.2. Diagnostic Device 1.2.1. Colposcopy 2. End User 2.1. Ambulatory Surgical Centers 2.2. Diagnostic Centers 2.3. Hospitals 2.4. Private Gynecologists’ Offices 2.5. Research & Academic Institutes 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. Abbott Laboratories 4.2. Becton, Dickinson and company 4.3. F. Hoffmann La-Roche Ltd. 4.4. Hologic, Inc 4.5. Micromedic Technologies Ltd. 4.6. OncoHealth Corporation 4.7. QIAGEN N.V. 4.8. Quest Diagnostics, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/cervical-dysplasia-diagnostics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 19, 2017 --( PR.com )-- Cervical dysplasia or cervical intraepithelial neoplasia (CIN) is precancerous change in the lining cells of the cervix of the uterus. It is mainly caused by infection with the human papillomavirus (HPV), but it does not produce any signs or symptoms. Cervical dysplasia is diagnosed by tissue biopsy or Pap smears according to the degree of abnormality. Pap test results indicate a squamous intraepithelial lesion (SIL) or cellular tissue damage or dysplasia. HPV testing to detect a "high-risk" type is done if a Pap smear is abnormal. Colposcopy, a gynecological procedure can also be used to detect and examine abnormalities of wall structures.Browse Cervical Dysplasia Diagnostics Market by Diagnosis Type (Diagnosis Test - Biopsy, HPV Test, Pap Smear Test), Diagnostic Device (Colposcopy), End Users (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, Private Gynecologists’ Offices, Research & Academic Institutes) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/cervical-dysplasia-diagnostics-market/The global cervical dysplasia diagnostics market segmentation is based on diagnosis type (diagnosis test - biopsy, HPV test, Pap smear test), diagnostic device (colposcopy), end users (ambulatory surgical centers, diagnostic centers, hospitals, private gynecologists’ offices, research & academic institutes).The global cervical dysplasia diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global cervical dysplasia diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global cervical dysplasia diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.Major players operating in the global cervical dysplasia diagnostics market and profiled in this report include Abbott Laboratories, Becton, Dickinson and company, F. Hoffmann La-Roche Ltd., Hologic, Inc., Micromedic Technologies Ltd., OncoHealth Corporation, QIAGEN N.V., and Quest Diagnostics, Inc.1. Diagnosis Type1.1. Diagnosis Test1.1.1. Biopsy1.1.2. HPV Test1.1.3. Pap Smear Test1.2. Diagnostic Device1.2.1. Colposcopy2. End User2.1. Ambulatory Surgical Centers2.2. Diagnostic Centers2.3. Hospitals2.4. Private Gynecologists’ Offices2.5. Research & Academic Institutes3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. Abbott Laboratories4.2. Becton, Dickinson and company4.3. F. Hoffmann La-Roche Ltd.4.4. Hologic, Inc4.5. Micromedic Technologies Ltd.4.6. OncoHealth Corporation4.7. QIAGEN N.V.4.8. Quest Diagnostics, Inc.To request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/cervical-dysplasia-diagnostics-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Rincon R.,OncoHealth | Cristobal I.,OncoHealth | Zazo S.,IIS Fundacion Jimenez Diaz | Arpi O.,Hospital del Mar | And 10 more authors.
Oncotarget | Year: 2015

The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A phosphorylation and deregulation SET and CIP2A as molecular contributing mechanisms to inactivate PP2A. Interestingly, restoration of PP2A activity after FTY720 treatment reduced cell growth, induced apoptosis and decreased AKT and ERK activation. Moreover, FTY720 led to PP2A activation then enhancing doxorubicin-induced antitumor effects both in vitro and in vivo. PP2A inhibition (CPscore: PP2A phosphorylation and/or CIP2A overexpression) was detected in 27% of cases (62/230), and associated with grade (p = 0.017), relapse (p < 0.001), negative estrogen (p < 0.001) and progesterone receptor expression (p < 0.001), HER2-positive tumors (p = 0.049), Ki-67 expression (p < 0.001), and higher AKT (p < 0.001) and ERK (p < 0.001) phosphorylation. Moreover, PP2A inhibition determined shorter overall (p = 0.006) and event-free survival (p = 0.003), and multivariate analysis confirmed its independent prognostic impact. Altogether, our results indicate that PP2A is frequently inactivated in breast cancer and determines worse outcome, and its restoration using PP2A activators represents an alternative therapeutic strategy in this disease.


Cristobal I.,OncoHealth | Rincon R.,OncoHealth | Manso R.,University Hospital Fundacion Jimenez Diaz | Carames C.,OncoHealth | And 4 more authors.
Clinical Cancer Research | Year: 2015

Purpose: SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic colorectal cancer (mCRC). Experimental Design:We studied the biologic effects of SET on cell growth, colonosphere formation, caspase activity, PP2A activation status, and sensitivity to oxaliplatin and FTY720 treatments. Moreover, we analyzed SET expression by immunostaining in 242 patients with mCRC. Results: SET deregulation promotes cell growth and colonosphere formation and inhibits PP2A, thereby impairing its antitumor effects. Moreover, SET reduces sensitivity to oxaliplatin in colorectal cancer cell lines, which is restored after FTY720 treatment. SET overexpression was detected in 24.8% (60 of 242) of patients with mCRC and determined significantly shorter overall (8.6 vs. 27 months; P < 0.001) and progression-free survival (7.1 vs. 13.7 months; P < 0.001), and poor response to oxaliplatin-based chemotherapy (P 1/4 0.004). Interestingly, its prognostic value was particularly evident in patients younger than 70 years and in those harboring KRAS mutations. Conclusions: SET overexpression is a frequent event in mCRC that plays a potential oncogenic role associated with worse outcome and resistance to oxaliplatin. Moreover, this alteration defines a subgroup of patients who could benefit from therapies containing PP2A activators such as FTY720. © 2014 American Association for Cancer Research.


Patent
OncoHealth | Date: 2011-02-17

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Detection of HPV DNAs, genomes, and/or oncoproteins by protein chips immunological assays can be used in early clinical screening for HPV infection and general diagnosis for cervical cancer and can be advantageous performed in a multiplexed test. Comparative detection of altered levels of HPV proteins and host proteins can performed in one or more assays. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.


Patent
OncoHealth | Date: 2016-03-23

Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Mononoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of invasive cervical cancer are provided. Cervical cancer biomarkers are identified and can be used in a detection method for early stage precancerous lesions as well as late stage cancer progression.


Trademark
OncoHealth | Date: 2012-12-11

Drug testing kits comprised of medical diagnostic reagents and assays for direct detection of human papillomavirus E6 and human papillomavirus E7 oncoproteins.


Trademark
OncoHealth | Date: 2012-01-09

cELISA is a name of tests for direct detection of biomarkers in whole cell on enzyme immuno assay platform.


Trademark
OncoHealth | Date: 2012-10-15

Drug testing kits comprised of medical diagnostic reagents and assays for direct detection of human papillomavirus E6 and human papillomavirus E7 oncoproteins.


News Article | May 3, 2011
Site: www.finsmes.com

OncoHealth Corporation, a Redwood City, CA-based developer of novel diagnostics for cervical cancer and other potentially deadly cancers caused by the human papillomavirus (HPV), has raised $1.6m in a Series A funding. The company intends to use the funds to participate in a comparative study currently being conducted by the federal government and a national reference laboratory to evaluate OncoHealth’s technology. “Companies trying to raise between $1 million and $4 million increasingly encounter a funding gap. The amount is too big for a single angel group and too small for most venture capitalists,” said Led by CEO Winnie Wan, Ph.D., OncoHealth plans to commercialize proprietary tests, which are designed to enable clinicians to triage HPV-infected patients based on their cancer-progression status and select the most effective treatments.

Loading OncoHealth collaborators
Loading OncoHealth collaborators